These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16563707)

  • 1. Clinical pharmacokinetics of voriconazole.
    Levêque D; Nivoix Y; Jehl F; Herbrecht R
    Int J Antimicrob Agents; 2006 Apr; 27(4):274-84. PubMed ID: 16563707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological aspects of the new triazole voriconazole.
    Ullmann AJ
    Ann Hematol; 2002; 81 Suppl 2():S50-1. PubMed ID: 12611077
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacology and clinical use of voriconazole.
    Thompson GR; Lewis JS
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
    Keirns J; Sawamoto T; Holum M; Buell D; Wisemandle W; Alak A
    Antimicrob Agents Chemother; 2007 Feb; 51(2):787-90. PubMed ID: 17116670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of voriconazole after oral and intravenous administration to horses.
    Davis JL; Salmon JH; Papich MG
    Am J Vet Res; 2006 Jun; 67(6):1070-5. PubMed ID: 16740104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation.
    Groll AH; Kolve H; Ehlert K; Paulussen M; Vormoor J
    J Antimicrob Chemother; 2004 Jan; 53(1):113-4. PubMed ID: 14657088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral voriconazole dose in children: one size does not fit all.
    Goutelle S; Larcher R; Padoin C; Mialou V; Bleyzac N
    Clin Infect Dis; 2010 Oct; 51(7):870; author reply 871. PubMed ID: 20809842
    [No Abstract]   [Full Text] [Related]  

  • 8. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alternative approach to determine oral bioavailability of drugs that follow Michaelis-Menten elimination: a case study with voriconazole.
    Verlindo de Araujo B; Farias da Silva C; Costa TD
    Pharmacology; 2010; 86(3):163-7. PubMed ID: 20714206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
    Brown J; Freeman BB
    Bone Marrow Transplant; 2005 Jul; 36(2):177. PubMed ID: 15908975
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.
    Clifton IJ; Whitaker P; Metcalfe R; Phillip M; Shaw N; Conway SP; Peckham DG
    J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443
    [No Abstract]   [Full Text] [Related]  

  • 13. Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans.
    Senthilkumari S; Lalitha P; Prajna NV; Haripriya A; Nirmal J; Gupta P; Velpandian T
    Curr Eye Res; 2010 Nov; 35(11):953-60. PubMed ID: 20958183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
    Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
    Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of voriconazole and dose individualization.
    Lutsar I; Hodges MR; Tomaszewski K; Troke PF; Wood ND
    Clin Infect Dis; 2003 Apr; 36(8):1087-8. PubMed ID: 12684928
    [No Abstract]   [Full Text] [Related]  

  • 17. Dosing voriconazole in an obese patient.
    Dickmeyer NJ; Kiel PJ
    Clin Infect Dis; 2011 Oct; 53(7):745. PubMed ID: 21846833
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh).
    Flammer K; Nettifee Osborne JA; Webb DJ; Foster LE; Dillard SL; Davis JL
    Am J Vet Res; 2008 Jan; 69(1):114-21. PubMed ID: 18167096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole.
    Lignell A; Johansson A; Löwdin E; Cars O; Sjölin J
    Clin Microbiol Infect; 2007 Jun; 13(6):613-9. PubMed ID: 17378925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of voriconazole during continuous venovenous hemofiltration.
    Spriet I; Wauters J; Willems L
    Ther Drug Monit; 2011 Jun; 33(3):372; author reply 372. PubMed ID: 21566509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.